IMMUNE RESPONSE IN MALIGNANT GLIOMA
Objective: Malignant gliomas are primary brain tumors with excessive mortality and high resistance to chemotherapy and radiotherapy. The survival time for glioblastoma multiforme is about 6-12 months. As key pathogenetic mechanisms are recognized the massive necrosis, angiogenesis and hypoxia withi...
Main Authors: | Iliyan Koev, E. Slavov, D. Staykov, K. Halacheva, Victoria Sarafian |
---|---|
Format: | Article |
Language: | English |
Published: |
Peytchinski Publishing
2010-07-01
|
Series: | Journal of IMAB |
Subjects: | |
Online Access: | http://www.journal-imab-bg.org/statii-10/vol16_b3_p17-19.pdf |
Similar Items
-
MULTIFOCAL GLIOBLASTOMA MULTIFORME PRECEDED BY A GEMISTOCYTIC ASTROCYTOMA AND DYSREGULATED IMMUNE RESPONSE.
by: Ilian Koev, et al.
Published: (2014-06-01) -
Research Progress About Glioma Stem Cells in the Immune Microenvironment of Glioma
by: Xiangyu Li, et al.
Published: (2021-09-01) -
Transcription factor ZBTB42 is a novel prognostic factor associated with immune cell infiltration in glioma
by: Yanwen Li, et al.
Published: (2023-01-01) -
Immune Checkpoint Inhibitors in Human Glioma Microenvironment
by: Amina Ghouzlani, et al.
Published: (2021-07-01) -
Immune Characteristics of LYN in Tumor Microenvironment of Gliomas
by: Chonghua Jiang, et al.
Published: (2022-02-01)